The case for routine use of adjuvant therapy in pancreatic cancer |
| |
Authors: | Kennedy Eugene P Yeo Charles J |
| |
Affiliation: | Department of Surgery, Thomas Jefferson University, Jefferson Medical College, Philadelphia, Pennsylvania 19107, USA. Eugene.Kennedy@jefferson.edu |
| |
Abstract: | Pancreatic cancer is a devastating disease with a poor prognosis for most patients. Surgical resection remains the cornerstone of treatment, providing the only realistic hope of long-term survival. Even with optimal surgical management, 5-year survival averages 15% to 20% for resectable disease. Progress is being made, however. Currently, the benefits of postoperative therapy for resected pancreatic ductal adenocarcinoma appear clear, and recommendations for such therapy appear to us to be well justified. Additional benefit to patients awaits the development of new agents, molecular targeted drugs, and novel approaches such as immunotherapy. |
| |
Keywords: | Pancreatic cancer adjuvant therapy chemoradiotherapy |
本文献已被 PubMed 等数据库收录! |
|